Cost-Effectiveness Analysis of the EndoBarrier Device in Patients with Type 2 Diabetes

There are multiple pharmacotherapy options for type 2 diabetes mellitus (T2DM) including injectable glucagon-like peptide 1 receptor agonists (GLP-1RA). EndoBarrier is an innovative impermeable liner implanted endoscopically into the proximal intestine for up to one year, before removal. We compare the cost-effectiveness of three strategies in patients with suboptimally controlled type 2 diabetes despite at least 6 months‘ liraglutide: EndoBarrier combined with  liraglutide; EndoBarrier without liraglutide; and liraglutide without EndoBarrier for  the treatment of obese patients with T2DM from a National Healthcare perspective.

ADA2018-abstract-Cost-effectiveness-analysis-submitted-8jan2018.pdf